ClinicalTrials.gg
SuspendedNCT01132521Updated Jan 17, 2018

Ulinastatin in Severe Acute Pancreatitis

A Phase 4 interventional study of ulinastatin and placebo in Pancreatitis, sponsored by Techpool Bio-Pharma Co., Ltd.. Suspended at 6 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-01-17.

Sponsored by Techpool Bio-Pharma Co., Ltd. (part of Shanghai Pharmaceuticals Holding Co., Ltd) · Phase 4, Interventional, and Treatment

Why this study was suspended
Revised project

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies in Pancreatitis with a site in China — 40 open to participants now, 44 under way, 2 of them phase 3. Pancreatitis · China.

Enrollment
26th of 75
252 · median 110
Started
2010
with 1 other
Phase 4
11 of 104
5 open now
Registered
1st of 104
by date

Among the 104 studies in Pancreatitis with a site in China, this one is the 26th largest by enrollment of the 75 interventional ones that give a count, is one of 2 that started in 2010, is one of 11 in phase 4, and was the 1st registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

40 of the 104 studies in Pancreatitis with a site in China are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Pancreatitis with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the effect of ulinastatin in the treatment and prevention of organ failure in severe acute pancreatitis.

Read the detailed description

About 20% of patients with acute pancreatitis have a severe course, and 10-15% of those with severe acute pancreatitis (SAP) die. Despite improvements in intensive care treatment during past few decades, effective therapies for acute pancreatitis are still limited.

Early deaths (within the first week) due to severe acute pancreatitis are generally caused by massive inflammatory responses which result in multiple organ failure. Although the exact mechanisms which trigger the inflammatory processes are not completely understood, it is generally accepted that autodigestion and activated leukocytes play important roles in the pathogenesis of acute pancreatitis. Activation of digestive enzymes causes pancreatic injury and results in an inflammatory response that is out of proportion to the response of other organs to a similar insult. The acute inflammatory response itself causes substantial tissue damage and may progress beyond the pancreas to a systemic inflammatory response syndrome, multi organ failure, or death.

UTI is a multivalent Kunitz-type serine protease inhibitor that is found in human urine and blood, it can stabilize lysosome membrane and inhibit lysosome function, inhibit the various enzymes and inflammatory response. Previous study proved that it protects against SIRS pathophysiology and subsequent organ damage induced via the modulation of the proinflammatory mediator, as well as chemokines. UTI has been widely used for the treatment and prevention of multiple organ failure in China, but there is few randomized, placebo controlled trial on ulinastatin. A large multicenter, randomized study is warranted. In this study, we aim to evaluate the effect of ulinastatin in the treatment and prevention of organ failure in severe acute pancreatitis with regular treatment in an add-on trial.

03

Conditions studied

  • Pancreatitis

Browse trials for

Keywords

  • ulinastatin
  • severe acute pancreatitis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of severe acute pancreatitis , severe acute pancreatitis adapted from the Atlanta classification:

Early Prognostic Signs: Ramson signs ≥3, APACHE II score ≥8 Organ Failure and/or Local Complications: Necrosis, Abscess, Pseudocyst;

  • Admission within 72h after onset of symptoms of pancreatitis
  • 18-70 years old
  • Signed the form

Exclusion criteria

Exclusion Criteria:

  • Pre-existing chronic renal insufficiency requiring hemodialysis or peritoneal dialysis
  • pre existing heart dysfunction or classification score above III
  • pregnancy or lactation
  • Allergy for ulinastatin
  • Received an drug or device within 90 days prior to entering study
  • serious mentally-ill patients including dementia
  • On the verge of death (estimated to be mortal in 12h).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    ulinastatin group

    Regular treatments plus ulinastatin. Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.

    Drug: ulinastatin

  • Placebo comparator
    placebo group

    Regular treatment plus placebo. Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.

    Drug: placebo

Interventions

  • Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.

    Also known as: UTI, urinary trypsin inhibitor, bikunin

  • Drugplacebo

    Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.

06

What researchers measure

Primary outcomes

  1. multiple organ dysfunction score

    Time frame: 8 days

  2. onset of (multiple) organ failure after randomized

    Time frame: 8 days

Secondary outcomes

  1. mortality

    Time frame: 8 days, 14 days and 28 days

  2. Incidence of complications

    Time frame: 8 days, 14 days and 28 days

  3. APACHE Ⅱ score

    Time frame: 8 days

  4. Need for surgical intervention

    Time frame: From admission to discharge

  5. Hospital stay and ICU stay

    Time frame: From admission to discharge

  6. CT-scan score

    Time frame: 8 days, 14 days

07

Study locations

6 sites
  • The First Affiliated Hospital of Sun Yat-Sen University
    Guangzhou, Guangdong, China
  • The First Clinical College of Harbin University
    Harbin, Heilongjiang, China
  • Wuhan Union Hospital of China
    Wuhan, Hubei, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu, China
  • West China Hospital
    Chengdu, Sichuan, China
  • Peking Union Medical College Hospital
    Beijing, China
08

References and documents

Publications

  • Wang CY, Zhao YP. Progress of therapeutic effect in severe acute pancreatitis: Mini-review of treatment viewpoints and technique improvements. Chin J Surg 44(13): 872-4, 2006. (Article in Chinese)
  • Maehara K, Kanayama N, Halim A, el Maradny E, Oda T, Fujita M, Terao T. Down-regulation of interleukin-8 gene expression in HL60 cell line by human Kunitz-type trypsin inhibitor. Biochem Biophys Res Commun. 1995 Jan 26;206(3):927-34. doi: 10.1006/bbrc.1995.1131. PubMed 7832806 ↗
  • Tsujino T, Komatsu Y, Isayama H, Hirano K, Sasahira N, Yamamoto N, Toda N, Ito Y, Nakai Y, Tada M, Matsumura M, Yoshida H, Kawabe T, Shiratori Y, Omata M. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol. 2005 Apr;3(4):376-83. doi: 10.1016/s1542-3565(04)00671-8. PubMed 15822043 ↗

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2010 (actual). Primary completion is estimated for Dec 2018, 102 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2010
First posted
May 28, 2010
StartActual
Jun 2010
Primary completionEst.
Dec 2018
CompletionEst.
Dec 2018
Last update
Jan 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01132521
Responsible party
Sponsor
First posted
May 28, 2010
Start date
Jun 2010
Primary completion
Dec 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Jan 17, 2018

Study contacts

Yupei Zhao, MD
study chair · Peking Union Medical College Hospital
Chunyou Wang, MD
principal investigator · Wuhan Union Hospital, China

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Urinastatin

Start the discussion